Corona Remedies Limited (NSE: CORONA) and Pfizer Ltd. (NSE: PFIZER) are both listed in the Pharmaceuticals industry. Corona Remedies has a market capitalisation of ₹14,481 Cr and Pfizer ₹17,811 Cr, as of 16 Nov 2026. Their P/E ratios are 77.6 and 24.5 respectively. Return on equity is 24.79% for Corona Remedies and 17.16% for Pfizer.
| Metric | Corona Remedies | Pfizer |
|---|---|---|
| NSE Symbol | CORONA | PFIZER |
| BSE Code | 544644 | 500680 |
| Share Price | ₹2,335.00 | ₹3,857.00 |
| Market Cap | ₹14,481 Cr | ₹17,811 Cr |
| P/E Ratio | 77.6 | 24.5 |
| Return on Equity | 24.79% | 17.16% |
| Return on Assets | 14.99% | 10.77% |
| Dividend Yield | 0.43% | 1.94% |
| Beta (1Y) | 0.08 | 0.26 |
| 1-Year Price Change | — | -24.2% |
| 3-Month Price Change | +10.2% | -22.9% |
| 52-Week Range | ₹1,336.60 – ₹2,719.30 | ₹3,589.00 – ₹5,257.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹441 Cr | ₹727 Cr |
| Quarterly Net Profit | ₹60 Cr | ₹313 Cr |
| Net Margin | 13.7% | 43.1% |
| EPS (Basic, Quarter) | ₹9.86 | ₹68.47 |
| Results Basis | consolidated | standalone |
| Headquarters | Ahmedabad, Gujarat | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
CORONA Remedies Limited, a pharmaceutical formulation company, develops, manufactures, and markets pharmaceutical products. It provides products in women’s healthcare, cardio-diabeto, pain management, urology, thyroid management, respiratory, nutraceuticals, gastroenterology, and other therapeutic areas. The company was incorporated in 2004 and is based in Ahmedabad, India.
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastrointestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products through a network of independent distributors. Pfizer Limited was…
Pfizer has a market capitalisation of ₹17,811 Cr, against ₹14,481 Cr for Corona Remedies as of 16 Nov 2026, about 1.2 times the size by market cap.
Corona Remedies has a P/E of 77.6 and Pfizer a P/E of 24.5 as of 16 Nov 2026.
Corona Remedies has a return on equity of 24.79% and Pfizer 17.16%.
Corona Remedies reported revenue of ₹441 Cr and net profit of ₹60 Cr for Q2 FY27. Pfizer reported revenue of ₹727 Cr and net profit of ₹313 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Pharmaceuticals on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.